Expect Intensified M&A Activity with Bio-Pharmaceutical Companies Leading to an Active 2021 & Beyond
While life sciences-focused mergers and acquisition activity in 2020 was expected to dip, at least a bit due to the […]
Bioclinica Acquires Brand New Silicon Valley AI Startup to Automate Medical Imaging & Accelerate Digital Diagnostic Development
Artificial intelligence (AI) will become an ever more important underlying force in the drug development process, from discovery through clinical […]
Trial Site Mavens: Edgemont Partners Matches Private Equity with Trial Site Organizations
As the clinical research space continues to adapt, advance and evolve, TrialSite chronicles a number of trends, including the ongoing […]
Emmes Expands Presence in Europe with Neox Acquisition: Crosses 1K Employee Mark and Grows in CRO Stature
A Rockville Maryland-based global, full-service clinical research organization (CRO) recently acquired a European-based CRO called Neox s.r.o., with over 150 […]
Velocity Clinical Research Strategic Move to Diversify Patient Enrollment Options: Southern California eStudySite Acquisition
Private equity-backed site organization roll-up Velocity Clinical Research purchased eStudySite, contributing two trial site locations in San Diego, California to […]
Bayer Acquires Gene Therapy Leader AskBio for up to $4 Billion Deal: Becoming a Global Gene Therapy Powerhouse
Germany-based Bayer acquired AskBio’s industry leading AAV-based gene therapy platform to accelerate its ability to bring urgently needed treatments to […]
Velocity Clinical Research Acquires Omega Medical Research, Expanding Its Reach to All Four Continental U.S. Time Zones
Paul Evans and Velocity are on the move again buying another research site in their quest to build a seamlessly […]
Flurry of Merck Deals to Enter COVID-19 Vaccine & Therapy Race—will Tap into Federal Dollars
Merck (NYSE:MRK), known as MSD outside the United States and Canada, has moved into the race to develop COVID-19 treatments, […]
How Gilead’s Newest Takeover Deal Will Bolster Its Cancer Strategy
Gilead Sciences (GILD) will buy cancer-focused player Forty Seven (FTSV) for $4.9 billion, the biotech company said Monday, sending FTSV stock rocketing. The deal […]
Astellas to Plug-in-and-Play to Vibrant South San Francisco Immuno-Oncology R&D Ecosystem with Xyphos Buy
Astellas Pharma Inc. acquired Xyphos Biosciences, Inc. to strengthen its immuno-oncology pipeline. With the acquisition Astellas gains Xyphos’ novel and proprietary […]
